लोड हो रहा है...
Secukinumab in the treatment of psoriasis: patient selection and perspectives
Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In Phase III clinical trials for each of these three indications, secukinumab has proven to be both highly e...
में बचाया:
| में प्रकाशित: | Psoriasis (Auckl) |
|---|---|
| मुख्य लेखकों: | , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Dove Medical Press
2018
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6202001/ https://ncbi.nlm.nih.gov/pubmed/30425963 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PTT.S146004 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|